Vanda Pharmaceuticals(US:VNDA) ZACKS·2026-02-11 23:15Core Insights - Vanda Pharmaceuticals reported a quarterly loss of $0.46 per share, significantly better than the Zacks Consensus Estimate of a loss of $2.18, representing an earnings surprise of +78.85% [1] - The company posted revenues of $57.22 million for the quarter ended December 2025, missing the Zacks Consensus Estimate by 2.78%, but showing an increase from $53.19 million year-over-year [2] - Vanda shares have underperformed the market, losing about 15.9% since the beginning of the year compared to the S&P 500's gain of 1.4% [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.24 on revenues of $64 million, and for the current fiscal year, it is -$1.47 on revenues of $275.85 million [7] - The estimate revisions trend for Vanda was favorable ahead of the earnings release, resulting in a Zacks Rank 2 (Buy) for the stock, indicating expected outperformance in the near future [6] Industry Context - The Medical - Biomedical and Genetics industry, to which Vanda belongs, is currently in the top 35% of over 250 Zacks industries, suggesting a favorable outlook for stocks within this sector [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]